Natera (NTRA, Financial) just delivered a mic drop moment for investors. The genetic testing heavyweight smashed expectations with a jaw-dropping 63.9% revenue boost in Q3, raking in $439.8 million compared to $268.3 million last year. The secret sauce? A 64.4% surge in product revenues and a 54.4% spike in oncology test volumes. Gross margins hit an impressive 61.8%, up from 45.1% a year ago, signaling the company's mastery in scaling operations and keeping costs in check.
And they're not stopping there. Natera raised its 2024 guidance, now targeting up to $1.64 billion in revenue and up to $75 million in net cash inflows. The buzz doesn't end with the numbers—breakthrough studies on colorectal cancer, published in Nature Medicine and presented at ESMO, are cementing its reputation as an innovation leader. CEO Steve Chapman summed it up best: “We're in a transformational year,” and the market clearly agrees.
Today's 20% stock rally shows investors are all-in on Natera's growth story. Analysts are calling out the company's killer combo of scaling test volumes, boosting margins, and delivering cash flow as the stuff of biotech dreams. With momentum like this, Natera is shaping up to be a must-watch player in the diagnostics space.
